Seth M Cohen1, Stephanie Misono. 1. Duke Voice Care Center, Division of Otolaryngology-Head & Neck Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA. seth.cohen@duke.edu
Abstract
OBJECTIVE: The goal of this systematic review was to examine the evidence for the use of the neuromodulating agents, amitriptyline, gabapentin, pregabalin, and baclofen, in the management of chronic, idiopathic cough patients. DATA SOURCES: Online databases, including PubMed, Embase, Cochrane Review, and Web of Science, and publications cited in bibliographies were used. REVIEW METHODS: Literature was searched by the 2 authors with a priori criteria for study selection. RESULTS: Eight relevant articles were identified, including 2 randomized controlled trials, 2 prospective cohort or case-series designs with consecutive patients, 1 retrospective case series of consecutive patients, 1 retrospective case series whose consecutive status was not known, and 2 case reports of 6 and 2 patients, respectively. Improvements in cough-specific quality of life were noted in the randomized controlled trials. Cough severity was reduced in studies that measured this outcome measure. In the remaining studies, cough symptoms were less after neuromodulator treatment. CONCLUSION: Benefit from neuromodulator treatment with amitriptyline, gabapentin, pregabalin, and baclofen in chronic, idiopathic cough patients was demonstrated. Further investigations using objective and subjective outcome measures are needed as well as studies exploring optimal dose, length of treatment, and relapse rates posttreatment.
OBJECTIVE: The goal of this systematic review was to examine the evidence for the use of the neuromodulating agents, amitriptyline, gabapentin, pregabalin, and baclofen, in the management of chronic, idiopathic coughpatients. DATA SOURCES: Online databases, including PubMed, Embase, Cochrane Review, and Web of Science, and publications cited in bibliographies were used. REVIEW METHODS: Literature was searched by the 2 authors with a priori criteria for study selection. RESULTS: Eight relevant articles were identified, including 2 randomized controlled trials, 2 prospective cohort or case-series designs with consecutive patients, 1 retrospective case series of consecutive patients, 1 retrospective case series whose consecutive status was not known, and 2 case reports of 6 and 2 patients, respectively. Improvements in cough-specific quality of life were noted in the randomized controlled trials. Cough severity was reduced in studies that measured this outcome measure. In the remaining studies, cough symptoms were less after neuromodulator treatment. CONCLUSION: Benefit from neuromodulator treatment with amitriptyline, gabapentin, pregabalin, and baclofen in chronic, idiopathic coughpatients was demonstrated. Further investigations using objective and subjective outcome measures are needed as well as studies exploring optimal dose, length of treatment, and relapse rates posttreatment.
Authors: Surinder S Birring; Sergio Matos; Ronnak B Patel; Benjamin Prudon; David H Evans; Ian D Pavord Journal: Respir Med Date: 2005-11-02 Impact factor: 3.415
Authors: Lorcan P A McGarvey; Carol Carton; Lucy A Gamble; Liam G Heaney; Richard Shepherd; Madeline Ennis; Joseph MacMahon Journal: Cough Date: 2006-06-16
Authors: Peter Gibson; Gang Wang; Lorcan McGarvey; Anne E Vertigan; Kenneth W Altman; Surinder S Birring Journal: Chest Date: 2016-01-06 Impact factor: 9.410
Authors: Rena Yadlapati; Alexander M Kaizer; Daniel R Sikavi; Madeline Greytak; Jennifer X Cai; Thomas L Carroll; Samir Gupta; Sachin Wani; Paul Menard-Katcher; Tsung-Chin Wu; Philip Weissbrod; Andrew M Vahabzadeh-Hagh; John E Pandolfino; Walter W Chan Journal: Clin Gastroenterol Hepatol Date: 2021-05-20 Impact factor: 11.382
Authors: Carolyn K Novaleski; Richard L Doty; Alissa A Nolden; Paul M Wise; Joel D Mainland; Pamela H Dalton Journal: J Voice Date: 2021-01-14 Impact factor: 2.300